The antiviral drug telbivudine prevents perinatal transmission of hepatitis B virus (HBV), according to a study in the June issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the ...
Jun 1, 2015
0
12
Warring armies use a variety of tactics as they struggle to gain the upper hand. Among their tricks is to attack with a decoy force that occupies the defenders while an unseen force launches a separate attack that the defenders ...
May 27, 2015
1
68
In a letter to the Medical Journal of Australia published today, a Monash University-led team is asking for hepatitis C virus patients to gain improved access to drugs to prevent liver related deaths.
May 18, 2015
0
65
Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease -hepatitis B virus (HBV) or hepatitis C virus ...
May 13, 2015
0
7
Hepatitis B stimulates processes that deprive the body's immune cells of key nutrients that they need to function, finds new UCL-led research funded by the Medical Research Council and Wellcome Trust.
May 11, 2015
0
37
A 12-week dose of an investigational three-drug hepatitis C combination cleared the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study in the May 5, 2015, issue of ...
May 5, 2015
0
69
Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These ...
Apr 25, 2015
0
6
Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis ...
Apr 25, 2015
0
11
New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation ...
Apr 25, 2015
0
7
Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with ...
Apr 25, 2015
0
5
